A B S T R A C T In the course of examining polymorphonuclear leukocyte (PMN) chemotaxis in patients w7ith systemic lupus erythematosus (SLE), we have found a previously undescribed serum inhibitor of complement (C5)-derived chemotactic activity. Serum from a 25-yr-old Black f'emale with untreated SLE, when activated with zymosan, failed completely to attract either her own or normal PMN. Incubation of normal PMN with the patient's serum did not aff'ect their subsequent random motility or chemotactic response toward normal zymosan-treated serum (ZTS). The patient's serum, however, did inhibit the chemotactic activity of normal ZTS and of column-purified C5-derived peptide(s), but had no effect on the chemotactic activity of either the synthetic peptide, N-formylmethionyl leucyl-phenylalanine or a filtrate prepared from a culture of Escherichia coli (bacterial chemotactic factor). The inhibitory activity in the patient's serum resisted heating at 56°C for 30 min and could be separated f'rom C5-derived chemotactic activity in the patient's ZTS (or normal ZTS that had been incubated with the patient's serum) by chromatography on Sephadex G-75. Despite its effect on C5-derived chemotactic activitv, the patient's serum did not influence two other C5-derived biologic activities: PMN lysosomal enzyme-releasing activity and PMN-aggregating activity. Chromatography of the patient's serum (65% ammonium sulfate pellet) on Sephadex G-200 yielded three distinct peaks of inhibitory activity. Two were This work was presented in part at the Eastern Section
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INTRODUCTION
Infection is a major cause of' morbidity and mortality among patients with systemic lupus erythematosus (SLE)' (1) (2) (3) (4) . Whereas treatment with adrenal corticosteroids is undoubtedly a contributing f;actor (3, 4) , there is also considerable evidence that the disease per se is associated with abnormalities of host defenses against infection. Staples et al. (4) , for example, have reported that the incidence of infections among patients with SLE was 10-fold greater than that observed in patients with rheumatoid arthritis and 5-f'old greater than that observed in a group of patients with nephrotic syndrome receiving comparable steroid therapy. Furthermore, the inf'ection rate for patients with SLE not receiving steroid therapy was four times that observed in similarly treated patients with other diseases. The majority of inf'ections that occur in patients with SLE are caused by pyogenic bacteria (3, 4) . Conseqluently, investigators have begun to examine some of'the major mechanisms of' defense against such infections in pa- ' Abbreviations used in this paper: C, complement; EGTA, ethylene glycol-bis (beta-aminoethyl ether) N,N'-tetra-acetic acid; N-formyl-metleu-phe, N-formylmethionylleucylphenylalanine; PMN, polymorphonuclear leukocyte(s); RBC, erythrocytes; SLE, systemic lupus erythematosus; ZTS, zymosan-treated serum. tients with SLE. Particular attention has been directed at the complement system and the function of peripheral blood polymorphonculear leukocytes (PMN) (5) (6) (7) (8) (9) (10) .
PMN are essential to normal host defenses by virtue of their ability to seek out, recognize, ingest, and kill invading microorganisms (11) . This requires a series of discrete steps; the first of which is directed migration (chemotaxis) of the cells toward invading pathogens. Such directed migration of PMN is mediated largely by those fluid-phase components of the complement system that are generated after activation of either the classic or alternative complement pathways (12, 13) .
Abnormalities of PMN chemotaxis have already been reported in some patients with SLE. For example, PMN from a small number of untreated patients have been found to migrate abnormally toward standard chemotactic stimuli (7, 9) . In contrast to this apparent cellular abnormality, Clark et al. (10) have found reduced complement-derived chemotactic activity in endotoxin-activated serum from 10 of 23 patients with SLE. PMN from all of these patients appeared to migrate normally toward a standard complement-derived stimulus. The precise nature of the abnormality observed in sera from these patients was not determined. Reduced chemotactic activity in endotoxin-activated serum could result either from a defect in the complement system (e.g. deficiency of one or more components) from which this activity is derived or to inactivators (or inhibitors) of chemotactic factors. Whereas the former possibility was investigated to some extent bv these authors (and excluded), the latter was not.
In the course of examining PMN chemotaxis in patients with SLE, we also have encountered abnormalities of complement-derived chemotactic activity in some activated sera (5 of 11 sera studied). As an explanation for some of these abnormalities, we have found in four of these sera a uniquely specific, reversible inhibitor of complement (C5)-derived chemotactic activity. Some of' the properties of this inhibitor are described in this report.
METHODS
Preparation olj leukocyte suspeitsionms and sera. Veniouis blood (32 ml) from healthy adtult donors and from patients with SLE was allowed to sediment at room temperature after mixing with 8.0( ml acid-citrate dextrose (National Instituites of Health formula A) and 20 ml 6.0% dextran (average mol wt 234,000) (Sigma Chemical Co., St. Louis, Mo.) in 140 mM NaCl. 35 Venous blood f'rom normal volunteers and patients with SLE was allowed to clot at room temperature. Serum obtained after centrifugation was either used f'resh or stored in ali(qtuots at -700C.
The criteria f'or diagnosis of'SLE were those of'the American Rheumatism Association (14) . Clinical manifestations, such as fever, skin rash, arthritis, serositis, and glomeruloniephritis, were used to arrive at the diagnosis of SLE activity. All of' the patients studiedl had active disease by these criterial. None, however, was infected or azotemic at the time of' sttudy.
Chemotacticfactors. C5-derived chemotactic activity was generated in f'resh or f'rozen (-70°C) Ltisoso inal ellzziflye rclecSe fromn PMN. Lysosomiial enzymne release f'rom cytochalasini B-treated PMN exposed to ZTS was meeasured as previouisly described (15, 23) . Ali(quiots (0.5 mnl) of' lekocvte stlispensios cmonttaining 4 x l(0 PMN vere (is-pensed into 10 x 75-mm polypropylene tubes. Cells were preinculbated wvith cvtochalasin B (5.0 gg/ml) (ICI Research Laboratories, Alderley Park, Cheshire, Eng.) in 0.1% dimethvl sulfoxide (Matheson, Coleman & Bell, East Rutherford, N. J.) at 37°C for 10 min bef'ore addition of' ZTS. This concentration of' dimethyl sulfoxide did not influeniee enzyme release or enizyme assavs. After incubation f'or 60 min at 37°C, the tubes vere centrifiged at 755 g for 10 min and the cell-f'ree superniates removed for enzyme assays. Activity in these supernates of' the lysosomal miarker enzyme, beta glucuroniidase was deterimiined after 18 h of' ineubation with phenolphthaleini glucuroinidate (Sigma Chemical Co.) as substrate (24) . The cytoplasmic enzyme, lactate dehydrogenase was determinied by the method of' W'acker et al. (25) . Release of lactate dehydrogenase was used as an indicator of cell viability (15, 23) . Enzyme activity released into supernates during the experimental period is expressed as percent of' the total activity recoverable f'rom simultaneously run duplicate reaction mixtures to which had been added the detergent, Triton X-100 (0.2% vol/vol) (Rohm and Haas Co., Philadelphia, Pa.). All values 'were corrected f'or background enzyme activity in mediumii blanks.
PMN aggregationl. Aggregation of' PMN by ZTS xvas measuired as previously described (26, 27) . For these experimenits, purified preparations of' PMN were obtained bv means of' Alternlative complement pathway actiuation in serumt.
Normal humani erythrocytes (RBC) were rendered stuseeptible to complement-mediated lysis by treatment wvith dithiothreitol (Sigma Chemical Co.) (29, 30) . Venotus blood f'rom nornmal v)olunteers was defibrinated in 125-ml Erlenmeyer flasks containing glass beads. After cenitriftigation at 100 g for 15 min, the stupernate and buffy coat were removed. The RBC were then washed three times in phosphate ( (Cell-f'ree supernates were assayed for hemoglobin wvith Drabkin's solution as previously describe(d (29 
RESULTS
Abntormiialities of chemotactic activity in zymitosan7-treated SLE sera. Sera obtained f'rom 11 patiemits with SLE were activated with zvmosan anid examinied for clhemotactic activity. ZTS from five of' these patients f;ailed to attract PMN comparably to normal ZTS (see below). ZTS f'romii one of' these patients (R. J.), a 25-yr-old Black f'emale wvith newly diagniosed untreated SLE, failed completely to attract normal PMN (Table  I) . 'Migration toward R. J. ZTS did not exceed that observed whenl onily buflfer containing albumin was added to the lower compartnments of the modified Boydeni chambers (random motility). To exclude the possibility that this apparent absence of chemotactic activity in R. J. ZTS was due to the presence of' an irreversible inhibitor of' cell motility, normal PMN were incubated with R. J. serum f'or 30 min at 37C, washed with buff'er, and examined f'or chemotactic responsiveness. As can be seen in Table I , such treatment of' normal PMN did not aff'ect their subsequent random motility or cheimiotactic response toward normal ZTS. Furthermore, the patient's own PMN were capable of' migrating in a directed fhashioin toward the same stimultus. As was the case witlh normal PIN, however, R. J. PMN exhibited only randomii motility in respoinse to R. J.
ZTS.
Complenment activationi in nornmal vs. R. J. serumn.
Inasmtilch as levels of C3 and C4 (measured immunochemically) in R. J. serum wvere modestly reduced (72 and 8 mg/dl, respectively), it was possible that the apparent absence of' chemotactic activity in R. J. ZTS was due either to a deficiency of' onie or more com- plement components or to an abnormality of complement activation, as consequences of her disease. This possibility was explored by measuring alternative complement pathway activation by zymosan in EGTAtreated normal vs. R. J. serum. As targets, we employed unsensitized RBC rendered susceptible to complement-mediated lysis by treatment with dithiothreitol (29, 30) . Addition of zymosan to EGTA-treated R. J.
serum caused hemolysis comparable to that observed when EGTA-treated normal serum was employed as a source of complement (Table II) . Thus, no gross abnormalities of alternative complement pathway activation by zymosan in R. J. serum could be detected. Effect of R. J. serum on chiemotactic activity in normal ZTS. Incubation for 30 min at 37°C of normal ZTS with either fresh or heated (56°C for 30 min) normal serum had no effect on chemotactic activity (Table   III) . Similar treatment with R. J. serum (fresh or heated), however, resulted in a dose-dependent diminution of chemotaxis (Table III and Fig. 1 ). As little Specificity of inhibitory activity int R. J. serum. In contrast to the effect of R. J. serum on the chemotactic activity in normal ZTS, no inhibitory effect was observed when this serum was incubated with various concentrations (all suboptimal) of either the bacterial chemotactic factor from E. coli or the chemotactic synthetic peptide, N-formyl-met-leu-phe (Table IV) . R. J. serum did, however, inhibit the activity of the chemotactic C5-derived peptide obtained after Sephadex G-75 chromatography of' normal ZTS.
Reversibility of the inhibitory effect of R. J. serumil on C5-derived chemnotactic activity. Normal ZTS and R. J. ZTS were subjected to molecular sieve chromatography on Sephadex G-75. Fractions were assayed for chemotactic activity and for inhibitory activity (by incubation with fresh normal ZTS) (Fig. 2) . As expected, normal ZTS yielded a major peak of chemotactic activity in the molecular weight range of 15,000-20,000 daltons ( Fig. 2A) . This peak corresponded to C5-derived chemotactic activity as evidenced by resistance to heating at 56°C for 30 min and susceptibility to inactivation by antibody to human C5 (15, 16) . Identical C5-derived chemotactic activity was recovered wheni R. J. ZTS (originally devoid of such activity, see Table  I ) was chromatographed. Chromatography of' R. J. ZTS also yielded inhibitory activity in fractions elutinig witlh the void volume (solid bars in Fig. 2B ). No such inhibitory activity ,vas recovered from normal ZTS (Fig. 2a) patients with SLE, when activated with zymosan, failed to attract PMN comparably to normal ZTS (Table  VI) . These same sera were also found capable of inhibiting C5-derived chemotactic activity after incubation with normal ZTS. All but the serum obtained from patient M. R. retained such inhibitory activity after heating at 56°C for 30 min. When these sera were examined for effects on the bacterial chemotactic factor from E. coli, only M. R. serum was found to have inhibitory activity (which was heat labile). It is very likely, therefore, that whereas M. R. serum contained only increased amounts of the previously described heat-labile chemotactic factor inactivator(s) (31) (32) (33) , sera from the other four patients contained heat-stable inhibitory activity specifically directed against the C5-derived chemotactic peptide(s) in ZTS. When serum from one of these patients (L. M.) was also subjected to ammonium sulfate fractionation and chromatography on Sephadex G-200, three peaks of inhibitory activity were found which were identical in every respect with the inhibitory activity isolated from R. J. serum (see Fig. 3 ). Obviously, too few patients with SLE were examined to determine whether the presence of such inhibitory activity correlated with any specific clinical or laboratory parameters of disease activity. (34, 35) and in patients with IgA myelomas (36) . This possibility was excluded not only by the finding that incubation of norimal PMN with the patient's serum failed to influence their subsequent random motility and chemotactic response to normal ZTS, but also by the demonstration that the patient's own PMN responded normally to this same stimulus (Table I) . Moreover, R. J. serum did not influence the migration of normal PMN toward other chemotactic stimuli (Table IV) . Secondly, studies were performed to determine whether there was an abnormality of chemotactic factor generation in the patient's serum as a consequence "IStimuli were preincubated with fresh or heated (56°C for 30 min) serum at 37°C for 30 min.
DISCUSSION
An Inhibitor of Chemotactic Activity in Systemic Lupus of either a defect in complement activation or a deficiency of complement components. Whereas levels of C3 and C4 (meastured immunochemically) were modestly low in the patient's serum, no major abnormalities of complement function could be detected. Studies employing RBC rendered susceptible to complement-mediated lysis by treatimient with dithiothreitol, revealed no gross abnormalities in the patient's serum of either alternative coimipleimient pathway activation by zymosan or hemolytic function (Table IL) . Furthermore, treatment of the patient's serum with zymosan resulted in the generation of C5-derived PMN lysosomal enzyme releasing activity (15, 23) (Table V) and PMN aggregating activity (26, 27) (Fig. 5) in amounts comparable to those generated in normal serum. These latter findings suggested not only that there were no major abnormalities involving C5, but also that C5 was being cleaved to yield biologically active peptides as a consequence of activation of the alternative complement pathway by zymosan.
Finally, studies were performed to determine whether the patient's serum contained an inhibitor or inactivator of complement (C5)-derived chemotactic activity. Indeed, "mixing" experiments yielded results that were quite consistent with this possibility (Table III) . Significant inhibition of chemotactic activity was observed when 5 ,l of R. J. serum was preincubated (370C for 30 min) with 100 ,ul of normal ZTS (Fig. 1) . That the inhibitory activity was directed against the chemotactic factor(s) in ZTS and not against the PMN was evident from the observation that mere mixing of R. J. serum with normal ZTS (without preincubationi) fLailed to cause inhibition of chemotactic activity (Table III) .
The inhibitory activity in R. J. serum resisted heating at 56°C for 30 min, was specific for the C5-derived chemotactic peptide(s) in ZTS (Table IV) , and was reversible. Both inhibitory and chemotactic activities could be recovered when R. J. ZTS was chromatographed on Sephadex G-75 employing phosphate-buf: fered 140 mM NaCl as the eluant (Fig. 2) . Separation of intact chemotactic and inhibitory activities was also obtained when mixtures of' R. J. serum and normal ZTS were similarly subjected to molecular sieve chromatography.
Chromatography of R. J. serum (65% ammonium sulfate pellet) on Sephadex G-200 yielded three distinct peaks of' inhibitory activity (Fig. 3) . Two were heat labile (560C for 30 min) and also inhibited the bacterial chemotactic factor (results not shown), whereas the third and most active peak (in the molecular weight range of' approximately 50,000-60,000) was resistant to heating at 56°C for 30 min and inhibited only C5-derived chemotactic activity. Identical results were obtained with serum from another patient (L. M.). Similarly treated normal serum, however, yielded only the two heat-labile peaks of inhibitory activity (Fig. 4) . Thus, the properties of' the major inhibitory activity in whole R. J. serum (and L. M. serum) appear to be qluite distinct from the properties of the previously described chemotactic f'actor inactivators (31) (32) (33) . The latter irreversibly inactivate diverse chemotactic stimuli, are of'higher molecular weight, are heat labile, and are present in small amounts in normal human seruim. Increased amounts of' these heat-labile inactivators have been found in patients with sarcoidosis (37), Hodgkin's disease (38) , hepatic cirrhosis (39) , and lepromatous leprosy (40) . Levels of activity in patients with SLE have not previously been reported. At least one of our SLE patients (M. R.) appeared to have increased levels of' chemotactic f;actor inactivator(s) in her serum (Table VI) . Of' 11 patients examined thus f'ar, 4 had only heat-stable inhibitory activity specifically directed at the C5-derived chemotactic peptide(s) in ZTS. Although an insufficient number of patients have been studied, preliminary observations seem to indicate a correlation between the presence of the inhibitor and disease activity. R. J. serum exhibited maximal inhibition of'C5-derived chemotactic activity at the time the diagnosis of' SLE was established and before any treatment was instituted. The inhibitory activity in her serum subsequently decreased by 50% after 3 mo of' treatment with prednisone, at a dose of 60 mg/ day. 9 mo later, when her disease was considered to be in remission, R. J. serum failed to show any inhibitory activity. Similar results have been noted in two other patients (P. G. and L. M.).
Neither the nature of the inhibitor of' C5-derived chemotactic activity in these SLE sera nor its precise mechanism of action can be determined f'rom the studies reported here. Its specificity and f'ailure to inactivate C5-derived chemotactic activity irreversibly suggest that it is capable of' merely associating with relevant peptides rather than altering them enzymatically. Further delineation of its mechanism of' action must await precise identification of'the biologically active peptides derived from C5 as a consequence of' complement activation. Whereas one of these peptides, the C5a anaphylatoxin, has been purified to homogeneity and demonstrated to have chemotactic and PMN lysosomal enzyme-releasing activities (41) (42) (43) , it remains unclear whether this peptide accounts for the bulk of the chemotactic activity generated in whole serum by complement activation (12, (44) (45) (46) (47) . The possibility remains that there are a number of closely related C5-derived peptides that possess similar biologic activities, either singly or in combination.
Human C5a is rapidly converted to C5ades Arg by a potent carboxypeptidase (i.e. carboxypeptidase B, anaphylatoxin inactivator) in serum or plasma (48) . The des Arg form of C5a is inactive as an anaphylatoxin and, in the absence of' other serum components, is virtually devoid of chemotactic activity (49) . It is, however, chem-otactically active in the presence of small amounts of normal uinactivated serum. These findings are similar to those of Wissler et al. (46) who described a serum "helper" factor ("cocytotaxin") required for the expression of chemotactic activity by C5a-derived peptides. In light of these findings, it is possible that the inhibitor described above might interact with either a C5a-derived chemotactic peptide or with a "helper" factor present in serum. In this fashion, it could influence chemotactic activity in ZTS without influencing PMN lysosomal enzyme-releasing activity or PMN-aggregating activity. Whatever the mechanism may be, the presence of this inhibitor of C5-derived chemotactic activity in patients with SLE may contribute, in part, to abnormal host defenses and increased susceptibility to infection due to pyogenic microorganisms.
